The State of New Mexico is characterized by ethnic diversity and unusual patterns of cancer incidence and mortality. A substantial number of New Mexicans are young, rural, poor, and medically uninsured and underserved. With a higher percentage of Hispanics and Native Americans than any other State, New Mexico's 1.8 million citizens are 45% White, 42% Hispanic, 10% Native American, 2% Black, and 1% other ethnic minorities. In addition to English and Spanish, our Pueblo, Navajo, Apache, and Ute Indian Tribes speak over twenty different languages and dialects. In this context, the mission of the University of New Mexico Cancer Research and Treatment Center (UNM CRTC) is to use its expertise in basic, translational, and clinical cancer research, cancer epidemiology, and community intervention to reduce the incidence and mortality of cancer in New Mexico's multiethnic populations. Participation in cooperative cancer prevention and treatment trials sponsored by the National Cancer Institute (NCI) and the MB-CCOP program, is a critical part of this mission. CRTC investigators have been contributing patients and scientific expertise to the NCI program since the Center opened in 1975. Currently funded with an NCI P20 Cancer Center Planning Grant, the CRTC has excellent research and primary cancer prevention programs supported by $83 million in total peer-reviewed funding. Among these is the New Mexico Tumor Registry (NMTR), one of the original Surveillance, Epidemiology and End Results (SEER) programs, now in its 30th year of NCI funding. The NMTR holds the world's largest database on cancer incidence and mortality in Hispanics and Native Americans and has documented strikingly different patterns of cancer incidence and mortality in these groups. Funded under the the MB-CCOP program since August 2000, the CRTC is building strong clinical cancer programs through the recruitment of 14 new oncology clinical specialists and the development of a new expanded clinical trials infrastructure at UNM and its affiliate sites. Together, the UNM CRTC and its Affiliates serve 80% of the cancer patients in the State. In close parallel with New Mexico's ethnic diversity, 52% of the patients currently enrolled from our MB-CCOP program to NCl-sponsored treatment and prevention trials are ethnic minorities: 31% Hispanic, 16% American Indian, 4% Asian, and 1% Black. Prior to being funded as a MB-CCOP program, the CRTC was a member institution of the Southwest Oncology Group (SWOG) and the Pediatric Oncology Group (POG); CRTC faculty continue to play significant leadership roles in these groups. Additional Research Bases include the National Surgical Adjuvant Breast and Bowel Project (NSABP) and most recently, the Eastern Cooperative Oncology Group (ECOG). Renewed funding of this MB-CCOP program will insure increased access and accrual of minorities to clinical trials, strengthen our Affiliate Network, facilitate the building of clinical trials programs with Hispanic and Native American Tribes and communities, and expand outreach to minority populations and the medically underserved in our region.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA086780-05
Application #
6779837
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
2000-08-17
Project End
2008-05-31
Budget Start
2004-06-01
Budget End
2005-05-31
Support Year
5
Fiscal Year
2004
Total Cost
$476,355
Indirect Cost
Name
University of New Mexico
Department
Pathology
Type
Schools of Medicine
DUNS #
868853094
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Napoles, A; Cook, E; Ginossar, T et al. (2017) Applying a Conceptual Framework to Maximize the Participation of Diverse Populations in Cancer Clinical Trials. Adv Cancer Res 133:77-94
Ginossar, Tamar (2016) Predictors of Online Cancer Prevention Information Seeking Among Patients and Caregivers Across the Digital Divide: A Cross-Sectional, Correlational Study. JMIR Cancer 2:e2
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9

Showing the most recent 10 out of 52 publications